Join IAG at the American College of Rheumatology Convergence 2022
Dr. Olga Kubassova, IAG’s CEO, and Julia O’Lynn, IAG’s Director of Bio Innovation, will be attending the American College of Rheumatology, ACR, meeting in Philadelphia, on November 10-14, 2022.
IAG’s team will be meeting with key biotech companies and addressing the challenges biotech companies face in rheumatology trials to explore IAG’s novel strategies to include advanced imaging biomarkers.
IAG partners with biotechnology and pharmaceutical companies and apply AI and Precision Medicine to accelerate drug approval.
IAG takes a holistic approach to biotech’s clinical development and brings together:
- An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
- Patented methodologies for quantitative assessment of treatment efficacy and safety
- Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
- Ensures that its bio-pharmaceutical clients gain the most benefits of early objective decision making on their treatment efficacy from utilizing advanced imaging techniques in their trials
Discover our risk assessment and management strategies to overcome the challenges in your rheumatology trial by contacting IAG at imaging.experts@ia-grp.com
About American College of Rheumatology (ACR) Convergence
The American College of Rheumatology’s Annual Meeting is your gateway to global rheumatology education. With over 450 sessions, the meeting provides boundless opportunities for professional development, networking, and first-hand access to the latest rheumatology research and clinical applications.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin